Treatment Resistant Major Depressive Disorder
7
0
1
3
Key Insights
Highlights
Success Rate
60% trial completion
Treatment Research
14 treatments under study, led by Intranasal Ketamine Esketamine
Research Leaders
8 sponsors active, led by Zylorion Health
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 55/100
28.6%
2 terminated out of 7 trials
60.0%
-26.6% vs benchmark
29%
2 trials in Phase 3/4
67%
2 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 3 completed trials
Clinical Trials (7)
Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD
DBS of the Lateral Habenula in Treatment-Resistant Depression
Repeated Intranasal Esketamine Plus Almond Therapy in Patients With Treatment Resistant Depression
Repeated Intranasal Esketamine Plus Almond Therapy in Participants With Treatment Resistant Depressive Disorder - 3 Month Extension Study
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder
Remotely Programmed Deep Brain Stimulation of the Bilateral Habenula for Treatment- Resistant Major Depression: An Open Label Pilot Trial
This is a Study to Determine the Antidepressant Effects of AZD6765
Research Network
Common Treatments
- Intranasal Ketamine Esketamine2
- Treatment As Usual2
- Azd67651
- Followup Period1
- Bupropion1
Active Sponsors
- Zylorion Health2
- Axsome Therapeutics, Inc.1
- National Institute of Mental Health (NIMH)1
- Ruijin Hospital1
- Massachusetts General Hospital1
Top Investigators
Amygdala Associates Inc.
Baylor College of Medicine
Amygdala Associates
National Institute of Mental Health (NIMH)